JP2018521959A - Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション - Google Patents

Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション Download PDF

Info

Publication number
JP2018521959A
JP2018521959A JP2017556585A JP2017556585A JP2018521959A JP 2018521959 A JP2018521959 A JP 2018521959A JP 2017556585 A JP2017556585 A JP 2017556585A JP 2017556585 A JP2017556585 A JP 2017556585A JP 2018521959 A JP2018521959 A JP 2018521959A
Authority
JP
Japan
Prior art keywords
btla
antibody
disease
hvem
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521959A5 (enExample
Inventor
カール エフ． ウェアー，
カール エフ． ウェアー，
ジョン セディー，
ジョン セディー，
ポーラ ノリス，
ポーラ ノリス，
Original Assignee
サンフォード−バーナム メディカル リサーチ インスティテュート
サンフォード−バーナム メディカル リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンフォード−バーナム メディカル リサーチ インスティテュート, サンフォード−バーナム メディカル リサーチ インスティテュート filed Critical サンフォード−バーナム メディカル リサーチ インスティテュート
Publication of JP2018521959A publication Critical patent/JP2018521959A/ja
Publication of JP2018521959A5 publication Critical patent/JP2018521959A5/ja
Priority to JP2022011710A priority Critical patent/JP2022044795A/ja
Priority to JP2024034837A priority patent/JP2024056047A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017556585A 2015-04-29 2016-04-29 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション Pending JP2018521959A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022011710A JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2024034837A JP2024056047A (ja) 2015-04-29 2024-03-07 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154484P 2015-04-29 2015-04-29
US62/154,484 2015-04-29
PCT/US2016/030138 WO2016176583A1 (en) 2015-04-29 2016-04-29 Modulation of immune response using btla agonist antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022011710A Division JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Publications (2)

Publication Number Publication Date
JP2018521959A true JP2018521959A (ja) 2018-08-09
JP2018521959A5 JP2018521959A5 (enExample) 2019-05-30

Family

ID=57198828

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017556585A Pending JP2018521959A (ja) 2015-04-29 2016-04-29 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2022011710A Pending JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2024034837A Pending JP2024056047A (ja) 2015-04-29 2024-03-07 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022011710A Pending JP2022044795A (ja) 2015-04-29 2022-01-28 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
JP2024034837A Pending JP2024056047A (ja) 2015-04-29 2024-03-07 Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Country Status (4)

Country Link
US (2) US11352428B2 (enExample)
EP (1) EP3288587A4 (enExample)
JP (3) JP2018521959A (enExample)
WO (1) WO2016176583A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022517441A (ja) * 2018-12-17 2022-03-08 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｂｔｌａ抗体
JP2022528005A (ja) * 2019-04-01 2022-06-07 レイクファーマ・インコーポレイテッド 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2023529215A (ja) * 2020-06-11 2023-07-07 オックスフォード ユニバーシティ イノベーション リミテッド Ｂｔｌａ抗体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521959A (ja) 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
KR20240110000A (ko) 2015-06-30 2024-07-12 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
JOP20190261A1 (ar) * 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
CN113603776B (zh) * 2018-02-12 2022-10-21 原启生物科技(上海)有限责任公司 Il17抗体及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) * 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
WO2015035063A2 (en) * 2013-09-05 2015-03-12 Sanford-Burnham Medical Research Institute MODULATION OF γδT CELLS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE359297T1 (de) * 2002-06-12 2007-05-15 Applied Research Systems Antagonisten für cxcr3-bindende cxc-chemokine
US8349320B2 (en) * 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
WO2010006071A1 (en) * 2008-07-08 2010-01-14 La Jolla Institute For Allergy And Immunology Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use
AU2007278054B2 (en) * 2006-07-24 2012-11-22 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
JP2018521959A (ja) 2015-04-29 2018-08-09 サンフォード−バーナム メディカル リサーチ インスティテュート Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) * 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
WO2015035063A2 (en) * 2013-09-05 2015-03-12 Sanford-Burnham Medical Research Institute MODULATION OF γδT CELLS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMMUNITY, vol. 39, JPN6020008551, 2013, pages 1082 - 1094, ISSN: 0004428610 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022517441A (ja) * 2018-12-17 2022-03-08 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｂｔｌａ抗体
JP2025000681A (ja) * 2018-12-17 2025-01-07 オックスフォード ユニヴァーシティ イノヴェーション リミテッド Ｂｔｌａ抗体
JP2022528005A (ja) * 2019-04-01 2022-06-07 レイクファーマ・インコーポレイテッド 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP7596298B2 (ja) 2019-04-01 2024-12-09 クリア・アイピー・ホールディングス・リミテッド・ライアビリティ・カンパニー 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2025041629A (ja) * 2019-04-01 2025-03-26 クリア・アイピー・ホールディングス・リミテッド・ライアビリティ・カンパニー 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
JP2023529215A (ja) * 2020-06-11 2023-07-07 オックスフォード ユニバーシティ イノベーション リミテッド Ｂｔｌａ抗体
JP7486616B2 (ja) 2020-06-11 2024-05-17 オックスフォード ユニバーシティ イノベーション リミテッド Ｂｔｌａ抗体

Also Published As

Publication number Publication date
US11352428B2 (en) 2022-06-07
US20220380468A1 (en) 2022-12-01
WO2016176583A1 (en) 2016-11-03
JP2022044795A (ja) 2022-03-17
EP3288587A1 (en) 2018-03-07
JP2024056047A (ja) 2024-04-19
US20180155426A1 (en) 2018-06-07
EP3288587A4 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
US20220380468A1 (en) Modulation of immune response using btla agonist antibodies
JP7158552B2 (ja) 抗Ｔｉｍ－３抗体及びその使用
JP7366543B2 (ja) Ｂｃｍａ結合分子及びその使用方法
JP2018502044A (ja) 抗ｐｄ−１抗体およびその用途
JP7559013B2 (ja) Ｂｔｌａ融合タンパク質アゴニストおよびその使用
CN114679909A (zh) MAdCAM靶向的免疫耐受
CA3080830A1 (en) Anti-lag-3 antibody and uses thereof
JP7328324B2 (ja) Ｔｉｍ－３に対する抗体およびその使用
EA043600B1 (ru) Слитые белки btla агонисты и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211001